NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)

A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)

German-speaking myeloma multicenter group

(GMMG)

Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment.

Sponsor

University of Heidelberg Medical Center

Information provided by (Responsible Party)

Prof. Dr. Hartmut Goldschmidt, University of Heidelberg Medical Center

German Study

---

ClinicalTrials.gov Identifier: NCT02495922

Official Title: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma